Insmed Incorporated (INSM) Stock
Key stats
- Market cap
- $26.49B
- Price / Earnings ratio
- -43.3x
- EPS (TTM)
- -$2.81
- Volume
- Loading
- 52-week high
- $212.75
- 52-week low
- $90.39
Source: third-party data provider, as of November 13, 2026
Compare with INSM
Recent news
INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance
INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance
INSM
What Insmed (INSM) Said on Its Q3 Earnings Call
What Insmed (INSM) Said on Its Q3 Earnings Call
INSM
Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
INSM
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
INSMNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 66.55
- MACD 12/26/9
- 2.89
- EMA 9 of MACD
- 0.12
- MACD histogram
- 2.77
- SMA 50
- $111.10
- Price above SMA 50
- EMA 50
- $109.57
- Price above EMA 50
- SMA 200
- $123.54
- Price below SMA 200
- EMA 200
- $129.46
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$1.03 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance
INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance
INSMWhat Insmed (INSM) Said on Its Q3 Earnings Call
What Insmed (INSM) Said on Its Q3 Earnings Call
INSMInsmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
INSMInsmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
INSM
Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
INSM
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
INSM
3 Healthcare Stocks Showing Why the Sector Still Has Momentum
3 Healthcare Stocks Showing Why the Sector Still Has Momentum
INSM
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
INSM
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
INSM
Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake
Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake
INSMNews tone: automated (AI) classification of the article's content, not a price prediction.
About Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. William H. Lewis J.D., M.B.A. | President, CEO & Chairman | 1969 |
| Mr. Roger Adsett M.B.A. | Chief Operating Officer | 1969 |
| Mr. Michael Alexander Smith J.D. | Chief Legal Officer & Corporate Secretary | 1978 |
| Dr. Martina Flammer M.B.A., M.D. | Chief Medical Officer | 1964 |
| Mr. Brian K. Kaspar Ph.D. | Chief Scientific Officer | 1974 |
| Bryan Dunn | Vice President of Investor Relations | — |
| Ms. Christie Camelio | Chief Compliance Officer | — |
| Ms. Claire Mulhearn | Vice President of Corporate Communications | — |
| Ms. S. Nicole Schaeffer M.B.A. | Chief People Strategy Officer | 1968 |
| Dr. Eugene J. Sullivan FCCP, M.D. | Chief Product Strategy Officer | 1965 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 66.55
- MACD 12/26/9
- 2.89
- EMA 9 of MACD
- 0.12
- MACD histogram
- 2.77
- SMA 50
- $111.10
- Price above SMA 50
- EMA 50
- $109.57
- Price above EMA 50
- SMA 200
- $123.54
- Price below SMA 200
- EMA 200
- $129.46
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $188.00
- Average
- $206.71
- High
- $220.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -9.8 | +2.1 | ||||||||||
| 2022 | -19.4 | +0.8 | -2.0 | -10.2 | -16.2 | +10.0 | +5.9 | +17.9 | -14.5 | -21.8 | +5.7 | +4.5 |
| 2023 | +12.3 | -5.7 | -15.8 | +12.3 | -5.7 | +9.7 | +6.5 | -1.1 | +11.5 | -1.2 | +0.1 | +16.9 |
| 2024 | -7.1 | -2.8 | -3.3 | -7.5 | +115.1 | +19.8 | +9.7 | +1.5 | -0.4 | -7.7 | +10.0 | -4.7 |
| 2025 | +9.5 | +4.7 | +0.0 | +0.0 | -4.0 | +40.4 | +9.9 | +25.2 | -0.9 | +28.7 | +11.6 | -17.7 |
| 2026 | -11.4 | -3.0 | +11.8 | -17.3 | -19.8 | +0.6 | -7.9 | +23.7 | -6.1 | +3.7 | +10.5 |
